Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units

What this Trial Is About

Arginine-vasopressin (AVP) is a hormone that affects blood vessel constriction, blood clotting, kidney function, and hormone release. Researchers are studying its use in patients experiencing shock, especially septic shock, where blood flow is dangerously low despite treatment. This study aims to understand how AVP is used in real-world critical care to support patients and to address uncertainties about its timing, dosing, and effects compared to other vasopressors like noradrenaline. This is a multicenter observational study that collects detailed clinical, laboratory, and heart ultrasound data from patients receiving vasopressin in the operating room or intensive care unit. The study records when vasopressin and noradrenaline are started and stopped, the doses used, and which medication is withdrawn first. It also looks at side effects, reasons for starting AVP, and how it affects heart function, blood flow, and other clinical signs over roughly one week. Participants will be monitored during their critical care stay, with data collected on vasopressor use, lab tests such as lactate, clinical signs like capillary refill and urine output, and heart ultrasounds. The study also tracks outcomes up to 90 days, including survival, time on breathing machines, kidney support, and hospital stay length. This detailed follow-up helps researchers better understand the role of vasopressin in managing shock and its medium to long-term effects.

Registry of Patients in Shock Treated With Vasopressin